Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
TipRanks on MSN
Omeros Signs Major Deal with Novo Nordisk
Omeros ( ($OMER) ) has issued an update. On October 10, 2025, Omeros Corporation entered into an Asset Purchase and License Agreement with Novo ...
A research team has outlined how synthetic biology can accelerate discoveries in plant–microbe interactions, offering ...
GlobalData on MSN
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
The biotech is also eligible to receive up to $2.1bn in development and commercial milestone payments from Novo Nordisk, ...
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a ...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in up ...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback